Physician profile
Asha Voss
NPI 1962407577
$2,191.15
in general payments reported to CMS, 2019-2025
26 companies · $305 in 2025
The $305 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $307 · 2020: $94.43 · 2021: $332 · 2022: $455 · 2023: $334 · 2024: $363 · 2025: $305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,003.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,002.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $437.78 | 2022-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $316.91 | 2019-2025 | Liletta, Lo Loestrin Fe |
| Hologic Sales and Service, LLC | $283.74 | 2019-2025 | Novasure |
| Baxter Healthcare | $186.42 | 2024-2025 | Perclot |
| Axonics, INC. | $145.58 | 2023-2024 | Axonics |
| Exeltis, USA INC. | $111.56 | 2021-2025 | Slynd |
| Coopersurgical, INC. | $91.17 | 2021 | |
| Sage Therapeutics, LLC | $56.76 | 2024-2025 | Zurzuvae |
| Conmed Corporation | $56.62 | 2020-2024 | Airseal |
| Novo Nordisk INC | $56.33 | 2019-2021 | |
| Therapeuticsmd, INC. | $55.17 | 2020-2022 | |
| Amgen INC. | $44.71 | 2019-2025 | Evenity |
| Applied Medical Resources Corporation | $40.08 | 2022 | |
| Daiichi Sankyo INC. | $36.58 | 2019-2021 | |
| Millicent US INC | $33.67 | 2019-2024 | Femring, Intrarosa |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $30.12 | 2021 | |
| Myovant Sciences INC. | $29.25 | 2021 | |
| Mayne Pharma Commercial LLC | $28.83 | 2023 | |
| Medtronic, INC. | $25.35 | 2025 | Interstim |
| Bayer Healthcare Pharmaceuticals INC. | $23.81 | 2019 | |
| Supernus Pharmaceuticals, INC. | $22.02 | 2025 | Qelbree |
| Evofem Biosciences, INC. | $21.21 | 2021 | |
| Pfizer INC. | $15.78 | 2025 | |
| Lupin INC. | $14.61 | 2019 | |
| Shield Therapeutics INC | $14.23 | 2024 | |
| Agile Therapeutics, INC. | $12.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asha Voss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.